Novartis AG (NYSE:NVS) Q3 2023 Earnings Call Transcript October 24, 2023 8:00 AM ET

Company Participants

Samir Shah - Global Head of Investor Relations

Vas Narasimhan - Chief Executive Officer

Harry Kirsch - Chief Financial Officer

Conference Call Participants

Andrew Baum - Citi

Kerry Holford - Berenberg

Emmanuel Papadakis - Deutsche Bank

Florent Cespedes - Societe Generale

Seamus Fernandez - Guggenheim Securities

Simon Baker - Redburn

Richard Vosser - JPMorgan

Graham Parry - Bank of America

Mark Purcell - Morgan Stanley

Stephen Scala - TD Cowen

Peter Welford - Jefferies

Operator

Good morning, and good afternoon, and welcome to the Novartis Q3 2023 Results Release Conference Call and Live Webcast. Please note that during the presentation, all participants will be in a listen-only mode, and the conference is being recorded. [Operator Instructions]. A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends.

With that, I would like to hand over to Mr. Samir Shah, Global Head of Investor Relations. Please go ahead, sir.

Samir Shah

Thank you very much, everybody, for joining once again. Just before we start, I'll just read you the safe harbor statement. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. For a description of some of these factors, please refer to the company's Form 20-F, its most recent quarterly results on Form 6-K that respectively were filed with and furnished to the US Securities and Exchange Commission.

With that, I'll hand the call to Vas.

Vas Narasimhan

Thank you, Samir, and thanks, everyone, for joining today's conference call. As you saw, we had some really strong results, but I wanted to also take a step back and note that this is an important moment for the company after many years of focusing the organization to become a pure-play medicines company. With the spin of Sandoz, we've completed that multi-year journey. Along the way, we've been able to create multiple important companies for the world in consumer health and eye care devices and now Sandoz in generics, alongside exiting our Roche stake and taking a number of shareholder-friendly actions, which we'll talk more about on the call. But I think this quarter demonstrates that Novartis is well positioned as a pure-play innovative medicines company to consistently drive top and bottom-line growth for the years to come.